Table 1.
Profile of major fatty acids, at baseline and with rosiglitazone
| Fatty Acids Percent of Total (%) | ||||
|---|---|---|---|---|
| |
Control |
SGA |
||
|
Fatty Acid |
Baseline |
Rosiglitazone |
Baseline |
Rosiglitazone |
| Palmitate 16:0 |
36.4 ± 1.5 |
37.9 ± 1.1 |
37.5 ± 0.7 |
37.7 ± 2.4 |
| Palmitoleate 16:1n-7 |
3.4 ± 0.1 |
3.09 ± 0.04 |
3.4 ± 0.1 |
3.3 ± 0.3 |
| Stearate 18:0 |
22.6 ± 0.9 |
29.1 ± 0.9* |
20.8 ± 0.6 |
22.4 ± 1.4c |
| Oleate 18:1n-9 |
19.7 ± 0.7 |
17.4 ± 0.4 |
20.0 ± 0.3 |
20.1 ± 1.2 |
| Vaccenate 18:1n-7 | 12.0 ± 0.5 | 10.4 ± 0.2 | 13.2 ± 0.3 | 12.1 ± 0.9 |
Cp < 0.05 compared with Control receiving the same treatment.
*p < 0.05 compared to the untreated state within the same group.
The fatty acid percentages of total are presented as the mean ± the standard error of the mean (SEM). With rosiglitazone treatment, Controls demonstrated increased stearate abundance.